Anoushka Kadam

Anoushka Kadam

Auto-generated profile, based on publicly available information

Anoushka Kadam

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Cancer Research
Verified
Journal Article
Closed access
RKRajendra Kumar
Rajendra Kumar
SJSheila Jonnatan
Sheila Jonnatan
DSDavid E. Sanin
David E. Sanin
VVVarsha Vakkala
Varsha Vakkala
AKAnoushka Kadam
Anoushka Kadam
LSLaura A. Sena
Laura A. Sena
Supraphysiologic androgen (SPA) treatment can paradoxically restrict the growth of castration-resistant prostate cancer (CRPC) with high androgen receptor (AR) activity, which is the basis for the use of bipolar androgen therapy (BAT) for patients with this disease. Although androgens are widely appreciated for enhancing anabolic metabolism, how SPA-mediated metabolic changes alter prostate cancer progression and therapy response is unknown. In this study, we report that SPA markedly increased intracellular and secreted polyamines in prostate cancer models. AR binding at enhancer sites upstream of the ornithine decarboxylase 1 (ODC1) promoter increased the abundance of ODC, a rate-limiting enzyme of polyamine synthesis, and de novo synthesis of polyamines from arginine. SPA-stimulated polyamines enhanced prostate cancer fitness, as dCas9-KRAB–mediated inhibition of AR regulation of ODC1 or direct ODC inhibition by difluoromethylornithine (DFMO) increased the efficacy of SPA. Mechanistically, AR activation combined with the loss of negative feedback by polyamines increased the activity of S-adenosylmethionine decarboxylase 1, leading to the depletion of its substrate, S-adenosylmethionine, and global protein methylation. These data provided the rationale for a clinical trial testing the safety and efficacy of BAT in combination with DFMO for patients with metastatic CRPC. Pharmacodynamic studies of this therapeutic combination in the first five patients in the trial indicated that this approach effectively depleted polyamines in plasma. Thus, the AR potently stimulates polyamine synthesis, which constitutes a vulnerability in prostate cancer treated with SPA that can be targeted therapeutically. Significance: Increased polyamine synthesis is a prominent metabolic change induced by the androgen receptor that drives tumor progression and confers a targetable vulnerability in advanced prostate cancer. See related commentary by Alizadeh-Ghodsi and Goldstein, p. 1095

2 March 2026
Verified
Other
Open access
PDF file
RKRajendra Kumar
Rajendra Kumar
SJSheila Jonnatan
Sheila Jonnatan
DSDavid E. Sanin
David E. Sanin
VVVarsha Vakkala
Varsha Vakkala
AKAnoushka Kadam
Anoushka Kadam
LSLaura A. Sena
Laura A. Sena
Characteristics of subjects in the Hamalainen autopsy study.

2 March 2026
Verified
Other
Open access
PDF file
RKRajendra Kumar
Rajendra Kumar
SJSheila Jonnatan
Sheila Jonnatan
DSDavid E. Sanin
David E. Sanin
VVVarsha Vakkala
Varsha Vakkala
AKAnoushka Kadam
Anoushka Kadam
LSLaura A. Sena
Laura A. Sena
SPA does not alter abundance of hypusinated eIF5A


2 March 2026
Verified
Other
Open access
PDF file
RKRajendra Kumar
Rajendra Kumar
SJSheila Jonnatan
Sheila Jonnatan
DSDavid E. Sanin
David E. Sanin
VVVarsha Vakkala
Varsha Vakkala
AKAnoushka Kadam
Anoushka Kadam
LSLaura A. Sena
Laura A. Sena
DFMO decreases putrecine induced by SPA and does not increase efficacy of AR inhibition

2 March 2026
Verified
Other
Open access
RKRajendra Kumar
Rajendra Kumar
SJSheila Jonnatan
Sheila Jonnatan
DSDavid E. Sanin
David E. Sanin
VVVarsha Vakkala
Varsha Vakkala
AKAnoushka Kadam
Anoushka Kadam
LSLaura A. Sena
Laura A. Sena
TableS4 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer